GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iNtRON Biotechnology Inc (XKRX:048530) » Definitions » Valuation Rank

iNtRON Biotechnology (XKRX:048530) Valuation Rank


View and export this data going back to 2011. Start your Free Trial

What is iNtRON Biotechnology Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


iNtRON Biotechnology Valuation Rank Related Terms

Thank you for viewing the detailed overview of iNtRON Biotechnology's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


iNtRON Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
137, Sagimakgol-ro, Jungwon-gu, Gyeonggi-do, Seongnam-si, KOR
iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business.